Invesaro

Stocks Health care CATX

NYSE · Health care

Perspective Therapeutics, Inc. (CATX)

It posted a net loss of $116.4M. In fiscal 2025 capital spending exceeded operating cash flow by $95.2M. At June 30, 2026 it held $48.5M in cash against $1.6M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.

What Perspective Therapeutics, Inc. does

Perspective Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker CATX.

Revenue and profit by year

Revenue
FY19: $7.3M $7.3M FY19FY20: $9.7M $9.7M FY20FY21: $10.1M $10.1M FY21FY22: $10.8M $10.8M FY22FY23: $0 $0 FY23FY23: $1.4M $1.4M FY23
Net income
FY19: -$5.1M -$5.1M FY19FY20: -$3.4M -$3.4M FY20FY21: -$3.4M -$3.4M FY21FY22: -$7.3M -$7.3M FY22FY23: -$10.8M -$10.8M FY23FY23: -$46.5M -$46.5M FY23FY24: -$79.3M -$79.3M FY24FY25: -$103.1M -$103.1M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025n/a-$113.6M-$103.1M-$1.40-$95.2M
2024n/a-$90.9M-$79.3M-$1.23-$72.7M
2023$1.4M-$40.9M-$46.5M-$1.74-$38M
2023$0-$8.7M-$10.8M-$0.82-$10.7M
2022$10.8M-$6.4M-$7.3M-$0.51-$8M
2021$10.1M-$3.4M-$3.4M-$0.31-$3.2M

Latest SEC filings

What Perspective Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 14, 2026
  2. September 8, 2026
  3. August 13, 2026
  4. August 10, 2026
    Quarterly report 10-Q · period to June 30, 2026
  5. August 10, 2026
  6. August 7, 2026
  7. August 3, 2026
  8. July 29, 2026
  9. July 20, 2026
  10. July 1, 2026

Recent insider filings (Forms 3, 4 and 144): 6, the latest on September 4, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about CATX

What does Perspective Therapeutics, Inc. do?

Perspective Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker CATX.

Is Perspective Therapeutics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $116.4M.

When did Perspective Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 14, 2026.

Similar companies

Follow CATX

Get an email when Perspective Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow CATX: get an email when it files

Where the numbers come from

Financial figures are the values Perspective Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.